PFIZER SHAREHOLDERS’ RESOLUTION

This Proposal is submitted by People for the Ethical Treatment of Animals and a collective of concerned shareholders.

WHEREAS, the Company has adopted a Laboratory Animal Care and Use policy (the “Animals Care Policy”) which appears on the Pfizer website;

WHEREAS, the Animal Care Policy asserts that Pfizer is committed to the “principles known as the 3R’s of animal research”;

WHEREAS, the 3R’s include i) the “refinement of the use of research animals to use less painful or the least invasive procedures whenever possible”; ii) the “reduction of the numbers of animals used in each study to the absolute minimum necessary to obtain valid results”; and iii) the “replacement of animal experiments with non-animal experiments such as mathematical models, computer simulations, and in vitro biological systems whenever appropriate”;

WHEREAS, it was reported in the Financial Times of London on July 29, 2004, that Pfizer and two other pharmaceutical companies² donated four million pounds (£4M) to British universities to promote medical research and training specifically using animals;

WHEREAS, the article reported that Pfizer and the other two companies stated “the donation was part of a greater willingness by their industry to back animal testing publicly”;

WHEREAS, a credibility gap arises from the Company’s purported Animal Care Policy and its affirmative promotion of animal testing as reported in the Financial Times;

NOW THEREFORE, BE IT RESOLVED, that the Company will make no further donations or contributions designed to promote the advancement of animal testing and will rescind the donation made to UK universities to the extent legally permissible; if the contribution

---

² The other two pharmaceutical companies are AstraZeneca and GlaxoSmithKline.
cannot be rescinded, the Company shall donate equivalent funds to promote non-animal based test methodologies.

**Supporting Statement:** Affirmatively supporting and promoting animal testing is wholly inconsistent with Pfizer’s Animal Care Policy of reducing, refining, and replacing animal based methods. Moreover, in the Proxy Materials for the 2004 annual meeting of shareholders, the Company relied on its commitment to the Animal Care Policy in an effort to convince shareholders to vote against a Shareholder Proposal Relating to *In Vitro* Testing. That Proposal sought support for five validated non-animal test methods. The Company opposed the Proposal, arguing that Pfizer was fully committed to its Animal Care Policy which rendered the Proposal unnecessary. Pfizer made the following statements in the 2004 Proxy Statement:

- “We are committed to the principles embodied by the 3Rs of animal research: seeking alternatives that Reduce, Replace or Refine our work with animals when such alternatives are available and appropriate.”
- “Pfizer has always supported the use of *in vitro* alternatives …”
- “We approach all research involving animals with the highest level of humane concern.”
- “[W]e are already working with regulators in an effort to increase the use of alternative models where such alternatives can be used appropriately.”

These statements cannot be harmonized with a policy of committing significant funds for the purpose of affirmatively promoting and publicly advancing animal testing and training graduate students to conduct animal experiments.

We urge our fellow shareholders to support this Resolution and bring Pfizer’s actions into harmony with the Company’s Animal Care Policy.